Last September, NeoFeed reported that Oncoclínicas would be replacing its CEO, Bruno Ferrari . At the time, the company denied this. And the businessman himself said he would remain in charge of the network of hospitals for cancer treatments , in an interview at the end of that month.
But NeoFeed was right. Oncoclínicas is indeed changing its CEO. And three names have emerged as candidates for Ferrari's position, who will now dedicate himself solely to the board of directors.
According to information obtained by NeoFeed , Spencer Stuart, which is conducting the process, is in talks with three individuals: Irlau Machado, former CEO of NotreDame Intermédica; Ricardo Bottas, current CFO of LATAM Airlines and former CEO of Amil; and Fabio Schvartzman, former CEO of Vale.
Machado, whose name was first published by the Brazil Journal , is reportedly in advanced talks. However, according to NeoFeed , no contract has yet been signed with him, nor with the other candidates.
The discussion about changing the CEO at Oncoclínicas has been led by Latache since last year and gained traction after the firm secured a majority on the board of directors at an extraordinary general meeting (EGM) held this week.
Of the slate proposed by Latache, five of the seven members were elected. The other two seats on the board went to nominees from Goldman Sachs, the company's largest individual shareholder.
Even with less weight than the Americans, Latache benefited from the support of other investors who gained greater influence in Oncoclínicas after the capital increase that converted part of the debt into equity . Among them were Santander, Arc Capital, and Banco Original.
In the new board, it was determined that Bruno Ferrari will be the vice-president, while Marcelo Gasparino will be the chairman of Oncoclínicas.
The departure of the current management team at Oncoclínicas is a long-standing desire of the market, following successive errors in the company's growth process after its IPO in 2021, which culminated in a high level of debt.
The trend is that the new CEO of Oncoclínicas will restrict the company's focus to specialized oncology care, its core business . This " back to basics" approach has been underway since last year, with divestments in non-priority areas such as the sale of hospitals and the termination of built-to-suit contracts.
